We are live on ! Find out more
HCM

Highbridge Capital Management Portfolio holdings

AUM $3.09B
1-Year Est. Return 31.19%
This Fund
S&P 500
This Quarter Est. Return
+2.73%
1 Year Est. Return
+31.19%
3 Year Est. Return
+54.53%
5 Year Est. Return
+78.37%
10 Year Est. Return
+191.39%
AUM
$8.22B
AUM Growth
+$272M
Cap. Flow
-$981M
Cap. Flow %
-11.94%
Top 10 Hldgs %
21.98%
Holding
1,489
New
477
Increased
218
Reduced
244
Closed
468

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$57.9M
2
SWN
Southwestern Energy Company
SWN
+$52.4M
3
XOM icon
ExxonMobil
XOM
+$49M
4
CL icon
Colgate-Palmolive
CL
+$45.4M
5
CF icon
CF Industries
CF
+$42.3M

Top Sells

Rank Stock Value
1
INTC icon
Intel
INTC
+$64.1M
2
META icon
Meta Platforms (Facebook)
META
+$58.9M
3
MON
Monsanto Co
MON
+$54.7M
4
CELG
Celgene Corp
CELG
+$53.6M
5
TGT icon
Target
TGT
+$52.1M

Sector Composition

Rank Sector Weight
1 Consumer Staples 9.92%
2 Healthcare 9.35%
3 Technology 6.84%
4 Consumer Discretionary 5.39%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRDO icon
926
CALL
Perdoceo Education
PRDO
$1.99B
$131K ﹤0.01%
27,900
-20,700
-43% -$120K
RALY
927
DELISTED
RALLY SOFTWARE DEV CORP
RALY
$129K ﹤0.01%
11,795
-6,023
-34% -$75K
BWEN icon
928
Broadwind
BWEN
$93.6M
$124K ﹤0.01%
+14,171
New +$162K
KWK
929
DELISTED
QUICKSILVER RESOURCES INC
KWK
$123K ﹤0.01%
+45,916
New +$125K
EXEL icon
930
Exelixis
EXEL
$13.3B
$117K ﹤0.01%
+34,577
New +$119K
CYTK icon
931
Cytokinetics
CYTK
$10.5B
$112K ﹤0.01%
+23,494
New +$143K
YUME
932
DELISTED
YuMe, Inc.
YUME
$111K ﹤0.01%
+18,848
New +$114K
FOLD
933
DELISTED
Amicus Therapeutics
FOLD
$109K ﹤0.01%
+32,508
New +$76.3K
MUX icon
934
McEwen Inc
MUX
$1.03B
$100K ﹤0.01%
3,450
-908
-21% -$21.9K
RDNT icon
935
RadNet
RDNT
$5.02B
$99K ﹤0.01%
+14,892
New +$85.6K
SLM icon
936
PUT
SLM Corp
SLM
$4.89B
$96K ﹤0.01%
+11,600
New +$102K
SLM icon
937
CALL
SLM Corp
SLM
$4.89B
$94K ﹤0.01%
+11,300
New +$99.6K
VSTM icon
938
Verastem
VSTM
$510M
$94K ﹤0.01%
+868
New +$94.4K
HLIT icon
939
Harmonic Inc
HLIT
$1.25B
$84K ﹤0.01%
11,300
-87,735
-89% -$631K
HIL
940
DELISTED
Hill International, Inc. Common Stock
HIL
$84K ﹤0.01%
+13,603
New +$86.4K
MDGL icon
941
Madrigal Pharmaceuticals
MDGL
$10.8B
$81K ﹤0.01%
+566
New +$82.7K
MTEM
942
DELISTED
Molecular Templates, Inc.
MTEM
$75K ﹤0.01%
115
-654
-85% -$433K
XNPT
943
PUT
DELISTED
XENOPORT, INC.
XNPT
$70K ﹤0.01%
+14,400
New +$61.1K
KEM
944
DELISTED
KEMET Corporation
KEM
$64K ﹤0.01%
+11,062
New +$61.5K
EGIO
945
DELISTED
Edgio, Inc. Common Stock
EGIO
$62K ﹤0.01%
+508
New +$48.2K
EMKR
946
DELISTED
Emcore Corp
EMKR
$46K ﹤0.01%
1,108
– –
C.WS.A
947
DELISTED
Citigroup Inc
C.WS.A
$38K ﹤0.01%
62,970
– –
C.WS.B
948
DELISTED
CITIGROUP INC WTS EXP (10/28/2018) (DE)
C.WS.B
$18K ﹤0.01%
584,537
– –
SVRA icon
949
Savara
SVRA
$1.12B
$9K ﹤0.01%
203
– –
A icon
950
Agilent Technologies
A
$39.1B
– –
-18,494
Closed -$739K
36 37
38
39 40

Similar funds

DCM
Donaldson Capital Management Evansville, Indiana $3.09B AUM 21.24% 1-Year Est. Return
CAM
Contour Asset Management New York $3.08B AUM 21.94% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
MRCP
Maple Rock Capital Partners Toronto, Ontario, Canada $3.07B AUM 157.2% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return

Highbridge Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Highbridge Capital Management held 1,489 positions worth $8.22B, up 3.4% from $7.94B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Highbridge Capital Management withdrew a net $981M in Q2 2014, closing 468 positions and reducing 244 holdings. Its most notable exit was Celgene Corp, an estimated $53.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 9.9% of assets, up from 9.2% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Highbridge Capital Management opened a new position in Bausch Health worth $38.6M.

  • Highbridge Capital Management's largest Q2 2014 buy was Bausch Health: 305,899 shares worth $38.6M.
  • Highbridge Capital Management added most to Citigroup in Q2 2014, an estimated $57.9M increase.
  • Highbridge Capital Management's biggest Q2 2014 reduction was Intel, cutting an estimated $64.1M.
  • Highbridge Capital Management fully exited Celgene Corp in Q2 2014, selling an estimated $53.6M.
  • Highbridge Capital Management's ten largest holdings make up 22% of its $8.22B portfolio in Q2 2014.
  • Highbridge Capital Management opened 477 new positions and closed 468 in Q2 2014.
  • Highbridge Capital Management's portfolio value rose 3.4% quarter-over-quarter to $8.22B.

Based on Highbridge Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.